Literature DB >> 9474005

Cardiovascular disease in patients with dysvascular amputation.

E J Roth1, K L Park, W J Sullivan.   

Abstract

Cardiovascular diseases are the most common causes of morbidity and mortality in individuals with peripheral vascular disease (PVD). Among patients who have undergone lower extremity amputation as a result of PVD, the prevalence of concomitant cardiovascular disease may be as high as 75%. Comorbid heart disease may complicate the postamputation course of recovery, delay initiation of rehabilitation training, and inhibit the achievement of maximal functional independence. A variety of methods have been used to assess cardiac status and risk in amputation patients undergoing physical training; these have included clinical evaluation, resting electrocardiography, and continuous dynamic electrocardiography during either standard physical therapy exercise or adapted ergometry. Several conditioning training programs have been developed to improve the cardiovascular fitness of patients with dysvascular amputation, the results of which have been favorable. These assessment and intervention strategies have extensive applicability in the clinical management of patients with dysvascular amputation.

Entities:  

Mesh:

Year:  1998        PMID: 9474005     DOI: 10.1016/s0003-9993(98)90301-x

Source DB:  PubMed          Journal:  Arch Phys Med Rehabil        ISSN: 0003-9993            Impact factor:   3.966


  3 in total

1.  Inter-limb weight transfer strategy during walking after unilateral transfemoral amputation.

Authors:  Ryo Amma; Genki Hisano; Hiroto Murata; Matthew J Major; Hiroshi Takemura; Hiroaki Hobara
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.379

2.  Prosthetic rehabilitation for older dysvascular people following a unilateral transfemoral amputation.

Authors:  Steven Barr; Tracey E Howe
Journal:  Cochrane Database Syst Rev       Date:  2018-10-23

3.  The risk of major cardiovascular events for adults with transfemoral amputation.

Authors:  Benjamin F Mundell; Marianne T Luetmer; Hilal Maradit Kremers; Sue Visscher; Kurtis M Hoppe; Kenton R Kaufman
Journal:  J Neuroeng Rehabil       Date:  2018-09-05       Impact factor: 4.262

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.